Post-Traumatic Stress Disorder (PTSD): Opportunity Analysis and Forecasts to 2028

Post-Traumatic Stress Disorder (PTSD): Opportunity Analysis and Forecasts to 2028

Summary

Post-Traumatic Stress Disorder (PTSD) is a psychiatric disorder that can occur in people who have experienced or witnessed a traumatic event such as a natural disaster, a serious accident, a terrorist act, war/combat, rape, or other violent personal assault. Symptoms include “re-experiencing” distressing memories, hypervigilance, avoidant behaviors, sweating, tremors, and dissociation.

The total Post-Traumatic Stress Disorder (PTSD) market was estimated to be worth US$211.4m across the seven major markets (7MM - US, France, Germany, Italy, Spain, UK and Japan) in 2018. This is expected to grow at a compound annual growth rate (CAGR) of 18.7% to reach US$1.2bn by 2028. Lack of efficacy is the most pressing unmet need in the Post-Traumatic Stress Disorder (PTSD) market and there have been no approved products to treat the disorder since 2001.

However, two drug candidates in the Post-Traumatic Stress Disorder (PTSD) pipeline that are expected to launch in the seven major markets (7MM - US, France, Germany, Italy, Spain, UK and Japan) by 2022 are set to revolutionize the treatment of the disorder, as evidenced by promising results in clinical trials. Zoloft and Paxil, currently the only two approved products in the seven major markets (7MM - US, France, Germany, Italy, Spain, UK and Japan) for Post-Traumatic Stress Disorder (PTSD), are antidepressants of the selective-serotonin reuptake inhibitors (SSRIs) class. The fact that Zoloft and Paxil work via the same mechanism of action means that they have the same unpleasant side effects as well as boxed warnings for impulsiveness and suicidal behaviors.

Brexpiprazole, an atypical antipsychotic approved for the treatment of major depressive disorder and schizophrenia, is in the pipeline for Post-Traumatic Stress Disorder (PTSD) and has shown efficacy when administered as an adjunct to Zoloft. The well-established safety profile and low frequency of adverse effects puts brexpiprazole in good stead to become the highest selling drug in the market, with forecasted annual sales of US$361.7m by 2028.

MDMA is a stimulant and late-stage pipeline product which was given breakthrough designation by the FDA, despite being a widely abused recreational drug. Its superior efficacy to marketed therapies and low frequency of administration are likely to be viewed favorably by physicians and patients alike. It is expected that in its first year on the market, MDMA is set to acquire a large patient share in the US as the first new drug for chronic Post-Traumatic Stress Disorder (PTSD) to be approved in 18 years. Brexpiprazole and MDMA are set to make up 47% of drug sales in 2022 and this figure will climb to 59% in 2028.

This potential for high sales whilst addressing the longstanding clinical unmet needs for the indication is clear assurance of the increasing efforts to add Post-Traumatic Stress Disorder (PTSD) to the list of psychiatric disorders that will experience market growth in the coming years and beyond.

The report “Post-Traumatic Stress Disorder (PTSD): Opportunity Analysis and Forecasts to 2028” provides an overview of Post-Traumatic Stress Disorder (PTSD), including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management. Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the Post-Traumatic Stress Disorder (PTSD) therapeutics market

Key Questions Answered

• What were the key Post-Traumatic Stress Disorder (PTSD) treatments in 2018?
• When will the late stage pipeline products launch, and how will it affect drug sales and the overall Post-Traumatic Stress Disorder (PTSD) market in the seven major markets (7MM - US, France, Germany, Italy, Spain, UK and Japan)?
• Which unmet needs will remain unaddressed in the forecast period and what opportunities remain for pharmaceutical companies?

Scope

• Overview of PTSD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
• Annualized PTSD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments (acute, chronic and delayed-onset) forecast from 2018 to 2028.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the PTSD therapeutics market
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for PTSD therapy. The most promising candidates in Phase III development are profiled.
• Analysis of the current and future market competition in the global PTSD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global PTSD therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PTSD therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.